Scientists identify potential new drug for inherited cancer

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have identified a new drug candidate for an inherited form of cancer with no known cure.

The new study showed the —known as FRAX97—slowed the proliferation and progression of in animal models of Neurofibromatosis type 2. This inherited type of cancer, caused by mutations in the anti-tumor gene NF2, leads to tumors of the that connects the inner ear to the brain.

The new compound, originally developed to treat neurodegenerative disease, targets a protein family known as p21-activated or PAKs. These kinases (enzymes that add a phosphate group to other proteins and change their function) play a critical role in the development of Neurofibromatosis type 2. PAK1 has also been implicated in the growth of breast and lung cancers.

"Our study shows that if we inhibit these kinases we can counter the formation of tumors in this brain disease," said Joseph Kissil, a TSRI associate professor who led the study.

In the new study, published in the October 4, 2013 issue of The Journal of Biological Chemistry, Kissil and his colleagues showed that the inhibitor slows down progression of Neurofibromatosis type 2 in animal models and reduces more than 80 percent of PAK1 activity.

Kissil notes a key challenge in developing drug candidates is finding potential agents that are both potent and highly selective for their targets—limiting its action to the desired arena and reducing unwanted side effects.

"This inhibitor turned out to be both potent and highly selective," he said. "The real question is why. We were able to show that it works through a unique mechanism."

While the binding site on PAK1 is quite large, it also contains a smaller pocket, a kind of backroom that juts off the larger site. The inhibitor not only takes up space in the larger site, but enters the back pocket as well. That extra binding gives the inhibitor its strong selectivity.

More information: Silvia Licciuli; Scott Troutman; Jasna Maksimoska; et al: "FRAX597, a Small Molecule Inhibitor of The P21-Activated Kinases, Inhibits Tumorigenesis of NF2-Associated Schwannomas," The Journal of Biological Chemistry, Vol. 288, Issue 40, 29105-29114, For more information on the paper, see: www.jbc.org/content/early/2013… M113.510933.abstract

Related Stories

Recommended for you

How a common antacid could lead to cheaper anti-cancer drugs

2 hours ago

A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years - and a group of cancer advocates want t ...

Vaccines may make war on cancer personal

2 hours ago

In the near future, physicians may treat some cancer patients with personalized vaccines that spur their immune systems to attack malignant tumors. New research led by scientists at Washington University ...

Funding to investigate an alternative to chemotherapy

3 hours ago

Professor Simon Rule, Professor in Haematology at Plymouth University Peninsula Schools of Medicine and Dentistry and Consultant Haematologist at Plymouth Hospitals NHS Trust, has been awarded a significant grant by Cancer ...

Enzyme may be key to cancer progression in many tumors

3 hours ago

Mutations in the KRAS gene have long been known to cause cancer, and about one third of solid tumors have KRAS mutations or mutations in the KRAS pathway. KRAS promotes cancer formation not only by driving ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.